> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bausch + Lomb Recalls enVista Intraocular Lenses
- URL: https://www.fdaweb.com/bausch-lomb-recalls-envista-intraocular-lenses/
- Published: 2025-04-01T12:00:00.000Z
- Updated: 2026-09-14T14:56:44.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5158929

Bausch + Lomb has recalled all enVista intraocular lenses (IOLs) due to increasing adverse event reports of toxic anterior segment syndrome (TASS) in conjunction with these IOLs. TASS is a rare, sterile inflammation of the anterior segment of the eye (the area between the cornea and iris) that typically occurs after intraocular surgery, according to NIH.

“Initially these reports centered on enVista Envy, but in recent days have extended to include enVista Aspire and enVista monofocal lenses, a [recall notice](https://www.bausch.com/globalassets/pdf/pr/brent-saunders-envista-customer-letter-final.pdf?ref=fdaweb.com) says. Because the root cause is unclear, the company says it decided to recall all enVista Envy and enVista Aspire IOLs, as well as certain lots of enVista monofocal lenses until there is a better understanding of the events.

Bausch + Lomb says that all reported TASS cases associated with enVista lenses responded quickly to treatment and did not result in removal of the lens. “We continue to test multiple lots and types of lenses, and we’re carefully analyzing the reports to detect patterns or common factors,” it adds.